They have to operate like a business Harry, and that includes battling for the revenues. But I agree that they're handing this very poorly. Most of the pharma companies have had questionable practices from time to time it seems. I think this one stands out so much for us because it affects MS patients and it's a deadly side effect.

I think this one will reflect in the revenue department if they don't change something so the patients who take the risks and pay the money for Tysabri can get the information they need to make informed decisions.